Development
Novartis AG
NVS
$118.08
$1.241.06%
NYSE
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -3.05% | 26.93% | |||
| Total Other Revenue | 13.87% | 2.65% | |||
| Total Revenue | -2.61% | 26.17% | |||
| Cost of Revenue | -3.30% | 46.05% | |||
| Gross Profit | -2.38% | 20.54% | |||
| SG&A Expenses | 11.35% | 21.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -20.19% | 15.56% | |||
| Total Operating Expenses | 1.70% | 28.77% | |||
| Operating Income | -13.42% | 20.08% | |||
| Income Before Tax | 53.16% | -36.76% | |||
| Income Tax Expenses | -769.23% | -88.07% | |||
| Earnings from Continuing Operations | 74.36% | -28.87% | |||
| Earnings from Discontinued Operations | 2,236.80% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 100.00% | -100.00% | |||
| Net Income | 381.54% | -23.96% | |||
| EBIT | -13.42% | 20.08% | |||
| EBITDA | -13.42% | 17.70% | |||
| EPS Basic | 384.38% | -23.18% | |||
| Normalized Basic EPS | -10.70% | 18.07% | |||
| EPS Diluted | 382.94% | -23.14% | |||
| Normalized Diluted EPS | -10.80% | 18.25% | |||
| Average Basic Shares Outstanding | -0.58% | -1.65% | |||
| Average Diluted Shares Outstanding | -0.48% | -1.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||